April 2, 1997JAMA
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group
Key result
Midodrine significantly improves standing systolic BP and symptoms over placebo in neurogenic orthostatic hypotension.
- P<.001
- n=171
Why the study?
The efficacy of midodrine in improving blood pressure and symptoms in patients with neurogenic orthostatic hypotension was evaluated.
Does midodrine improve standing systolic blood pressure and symptoms in patients with neurogenic orthostatic hypotension?
Population
171 patients with neurogenic orthostatic hypotension
Comparison
Midodrine 10 mg three times per day vs placebo
Design
Multicenter randomized double-blind placebo-controlled study
Follow-up
6 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports midodrine for neurogenic orthostatic hypotension; confirms randomized efficacy and bolsters guideline-endorsed use.
Study Design
Type
RCT (n=171)
Blinding
Double-blind
Randomization
randomized
Multicenter
Yes
Structured PICO
Does midodrine improve standing systolic blood pressure and symptoms in patients with neurogenic orthostatic hypotension?
P
Population
171 patients with neurogenic orthostatic hypotension evaluated in a 6-week randomized, placebo-controlled trial.
I
Intervention
Midodrine 10 mg 3 times per day
C
Comparator
Placebo
O
Outcome
Improvement in standing systolic BP, symptoms of lightheadedness, and a global symptom relief score (by the investigator and patient separately)patient reported
Main Result
p-value: p=<.001
Midodrine 10 mg three times daily significantly improves standing systolic blood pressure and orthostatic symptoms in patients with neurogenic orthostatic hypotension.
Cite This Study
Phillip A. Low (1997) conducted an RCT in neurogenic orthostatic hypotension (n=171). Midodrine vs. Placebo was evaluated on improvement in standing systolic BP, symptoms of lightheadedness, and a global symptom relief score (p=<.001). Midodrine significantly improved standing systolic blood pressure (P<.001) and reported symptoms (P=.001) compared to placebo in patients with neurogenic orthostatic hypotension.